ArticleAnnals of hematology2026
A novel prognostic index predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP immunochemotherapy.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The International Prognostic Index (IPI) and IPI related prognostic indexes are widely used for risk-stratification in lymphoma. However, identifying poor prognostic group patients remains a significant objective. This study aimed to develop a predictive prognostic model for DLBCL treated with R-CHOP immunochemotherapy. A cohort comprising 167 individuals newly diagnosed with DLBCL between January 2016 and June 2021 at Jiangsu cancer hospital, Nanjing Medical University were enrolled for investigation. Univariate and multivariate Cox analysis were used for variable selection. The Akaike information criterion (AIC) guided the selection of factors for constructing the nomograms, along with a novel prognostic index for assessing both progression-free survival (PFS) and overall survival (OS). Internal validation was performed with the bootstrap method(B = 1000). Age, Lactate dehydrogenase (LDH), stage, extra-nodal sites and absolute CD4 + T cell counts (ACD4C) were associated with both PFS and OS. These discerned prognostic factors were subsequently employed in constructing nomograms for PFS and OS, respectively. The C-indexes of Internal validation performed with the Bootstrap method were 0.76 (PFS: 95%CI 0.67-0.80),0.81(OS:95%CI 0.72-0.85), respectively. The calibration plots, alongside internal bootstrap resampling, demonstrated commendable consistency between predictions and observations. For enhanced clinical applicability, we devised a novel immune prognostic index, categorizing DLBCL patients into four distinct risk groups: low, low-intermediate, high-intermediate, and high risk, corresponding to 0, 1-2, 3, 4-5 risk factors respectively. Kaplan-Meier analysis underscored the superior discriminatory capacity of the immune index in assessing the prognosis across various risk groups. The proposed immune index is a useful tool to predict the prognosis of DLBCL patients treated with R-CHOP immunochemotherapy in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.